For the Inventor, By the Inventor

Enter assignee name

London, United Kingdom

Mereo Biopharma 1 Limited

USPTO Granted Patents = 10

EPO Patents = 8

Forward Citations = 18

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Jacqueline Parkin (5 out of 5 patents)

Osama Suleiman (3 out of 11 patents)

Colin Orford (3 out of 3 patents)

4. Cyril Clarke (3 out of 3 patents)

5. Colm Farrell (3 out of 3 patents)

6. Stefan De Buck (3 out of 7 patents)

7. Lucia Romero Perez (3 out of 3 patents)

8. Cornelius Stephan Harlacher (3 out of 3 patents)

9. Stewart Jones (3 out of 3 patents)

10. Alastair McKinnon (1 out of 1 patent)

11. Benjamin Martin (1 out of 8 patents)

12. Paul Andrew Ford (1 out of 1 patent)

13. Mark Meisenbach (1 out of 1 patent)

14. Carmen Ruiz (1 out of 1 patent)

15. Niek Johannes Ronde (1 out of 1 patent)

10 patents: Sort by Forward Citations

1. 11701341 - Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease (2023-07-18),

2. 11649213 - Synthetic method for the preparation of a 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol compound (2023-05-16),

3. 11434204 - Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide (2022-09-06),

4. 11234967 - Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease (2022-02-01),

5. 11129810 - Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease (2021-09-28),

6. 10995071 - Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide (2021-05-04),

7. 10934260 - Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide (2021-03-02),

8. 10617674 - Dosage regimen for the treatment of acute exacerbations of inflammatory conditions (2020-04-14),

9. 10603306 - Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease (2020-03-31),

10. 9339491 - Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease (2016-05-17),

Company Overview

Mereo Biopharma 1 Limited is a biopharmaceutical company based in London, specializing in the development of innovative therapeutics for rare diseases and oncology. The organization focuses on advancing its proprietary product candidates through clinical trials, aiming to address unmet medical needs. Mereo leverages its expertise in drug development and regulatory processes to bring novel treatments to market, contributing to the evolving landscape of biopharmaceuticals in the UK and beyond.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

10 Patents

#323 in London

#1,731 in United Kingdom

#56,047 in the World

London, United Kingdom

Mereo Biopharma 1 Limited

Forward Citations = 18

16 inventors:

Jacqueline Parkin (5 out of 5 patents)

Osama Suleiman (3 out of 11 patents)

Colin Orford (3 out of 3 patents)

4. Cyril Clarke (3 out of 3 patents)

5. Colm Farrell (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mereo Biopharma 1 Limited. Retrieved from https://idiyas.com/company/mereo-biopharma-1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…